| ALK

Our solutions

Managing allergies

Solutions for the world's allergies

We want to make a difference by offering solutions for everyone who is touched by allergy – through a comprehensive range of products, services and resources that offer a fast-track to a more balanced life.

Our solutions

Consumer healthcare
We have expanded with a new consumer healthcare division that offers new products and services via a webshop to help people manage their allergies.
Diagnostics
The first step in being able to optimally treat any allergy is getting a definitive diagnosis. As well as treatments, ALK also makes allergen extracts for use in allergy diagnosis tools, such as skin prick tests.
Allergy vaccines
Allergy immunotherapy is a treatment for respiratory allergies that works by treating the underlying cause of the allergy. At ALK, we specialise in evidence-based products that rebalance the immune system by gradually building up tolerance to allergens.
Emergency treatment
For some people, exposure to specific food or a bee or wasp stings can trigger an acute allergic reaction also known as anaphylaxis. This can lead to respiratory arrest if quick and effective emergency treatment is not given.
Last updated: 05.07.2019

Patients

Do you suffer from allergic disease?

Patients

Worldwide industrialisation and lifestyle changes have had a major impact on the development of respiratory allergies. Allergy immunotherapy can help patients to take control of their allergies by reprogramming their immune system.

Addressing a global problem

Respiratory allergy - facts and figures
Globally, 400-500 million people are affected by allergic rhinitis, and 10-20% of these have symptoms which are not well controlled. People who experience insufficient effect from symptomatic medication can benefit from allergy immunotherapy.
The connection beween allergic rhinitis and allergic asthma
It is well established that respiratory allergies can lead to both allergic rhinitis and allergic asthma, which although often treated separately in the past, are increasingly being seen as different manifestations of a single condition.
Treating allergy
The most important difference between allergy immunotherapy treatment and treatments that only suppress allergy symptoms for a short time is that immunotherapy reprogrammes the body to induce immunological tolerance, thus altering the course of the disease.
Last updated: 09.07.2019

Front Page

ALK

Celebrating the past and future of allergy solutions for life

Front_page_1
Front_page_2

Pioneers in helping people with allergies

For 100 years, ALK has consistently devised and developed major advances for the treatment of allergy

News

  • Post date
    05/04/2026
    Three-month interim report (Q1) 2026 (unaudited)
  • Post date
    05/04/2026
    ALK upgrades its full-year outlook
  • Post date
    04/28/2026
    Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026
  • Post date
    04/20/2026
    ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
  • Post date
    04/15/2026
    neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada
  • Post date
    04/08/2026
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
  • Post date
    04/01/2026
    Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
  • Post date
    03/31/2026
    EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis
  • Post date
    03/16/2026
    Annual General Meeting in ALK-Abelló A/S held on 16 March 2026
ALK Corporate Strategy 2024-2028
As the pioneers of allergy solutions, we are stepping into the next 100 years with a mission to help more people, with more solutions, more efficiently. We call it Allergy+.
100 Years of Pioneering Allergy Solutions
A new book has been written about ALK’s fascinating development in the field of allergy
The hunt for a vaccine – a podcast in five episodes
A fascinating story about ALK and the company’s 100 years of hunting allergy vaccines have been turned into a captivating podcast.

ALK in brief

Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.
Last updated: 04.06.2024